Procept Biorobotics Corp Überblick
Branche: Healthcare Equipment & Supplies
Sektor: Healthcare
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic
Research-Überblick
Letztes Berichtsdatum 2026-08-04Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Procept Biorobotics Corp (PRCT): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- PRCT · Nasdaq · MIC XNAS
- Land
- United States
- Handelswährung
- USD
- Branche
- Healthcare Equipment & Supplies
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-08-04
Primärquellen
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-08-04
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Procept Biorobotics Corp für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $94.5M (reported). Net loss was -$26.9M. Adjusted EBITDA was -$11.3M (+42% YoY).
Revenue
$94.5M
reported
Net loss
-$26.9M
reported
Adjusted EBITDA
-$11.3M
+42% YoY
Was sich verändert hat
- Revenue reported to $94.5M.
- Adjusted EBITDA +42% YoY to -$11.3M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Bericht öffnen
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
SEC filing
10-Q
Aug 05, 2026
SEC filing
8-K
Aug 04, 2026
SEC filing
10-Q
Apr 30, 2026
SEC filing
8-K
Apr 29, 2026
Earnings release
Earnings release
Apr 29, 2026
SEC filing
10-K
Feb 26, 2026
SEC filing
8-K
Feb 25, 2026
Earnings release
Earnings release
Feb 25, 2026
SEC filing
10-Q
Nov 05, 2025
SEC filing
8-K
Nov 04, 2025
Earnings release
Earnings release
Nov 04, 2025
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Headline from PR Newswire: PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit.
PROCEPT BioRobotics Corporation (PRCT) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 22, 2026 Lead Plaintiff Deadline
Headline from PR Newswire: PROCEPT BioRobotics Corporation (PRCT) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 22, 2026 Lead Plaintiff Deadline.
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law
Headline from GlobeNewswire: PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law.
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law
Headline from GlobeNewswire: PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law.
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law
Headline from GlobeNewswire: PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law.
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Headline from PR Newswire: PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit.
Gewinn je Aktie
Score 3.00/5
Procept Biorobotics Corp boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Healthcare Equipment & Supplies industry
, AmerisourceBergen
, Insulet Corporation
, NuVasive Inc
are companies with high ratings.
Eigenkapitalrendite
Score 1.54/5
Procept Biorobotics Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Score 1.48/5
Procept Biorobotics Corp
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Score 2.73/5
Procept Biorobotics Corp
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.
Finanzkennzahlen
Jährlich
Quartalsweise
Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen